Relay Therapeutics (RLAY) Payables (2019 - 2026)

Relay Therapeutics (RLAY) has reported Payables for 8 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 51.43% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 51.43% YoY), while the FY2025 annual figure was $7.7 million, down 45.34% from the prior year.
• Payables slipped to $4.1 million in Q1 2026 per RLAY's latest filing, from $7.7 million in the prior quarter.
• Across five years, Payables topped out at $14.8 million in Q2 2023 and bottomed at $2.8 million in Q3 2025.
• Historically, Payables has averaged $8.8 million across 5 years, with a median of $8.4 million in 2025.
• Annual changes were most pronounced in 2023 — Payables surged 243.99% — and 2025, when it tumbled 59.92%.
• Relay Therapeutics' Payables stood at $10.6 million in 2022, then fell by 12.92% to $9.2 million in 2023, then jumped by 53.05% to $14.1 million in 2024, then plunged by 45.34% to $7.7 million in 2025, then slumped by 46.74% to $4.1 million in 2026.
• Business Quant data shows RLAY's Payables at $4.1 million in Q1 2026, $7.7 million in Q4 2025, and $2.8 million in Q3 2025.